WEWilliam Eger

William Eger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


William Eger has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Nurse Practitioner–Led Integrated Rapid Access to HIV Prevention for People Who Inject Drugs (iRaPID): Protocol for a Pilot Randomized Controlled Trial

    by Antoine Khati, Frederick L Altice, David Vlahov, William H Eger, Jessica Lee, Terry Bohonnon, Jeffrey A Wickersham, Francesca Maviglia, Nicholas Copenhaver, Roman Shrestha

    Background: The ongoing volatile opioid epidemic remains a significant public health concern, alongside continued outbreaks of HIV and hepatitis C virus among people who inject drugs. The limited access to and scale-up of medications for opioid use disorder (MOUD) among people who inject drugs, coupled with multilevel barriers to pre-exposure prophylaxis (PrEP) uptake, makes it imperative to integrate evidence-based risk reduction and HIV prevention strategies in innovative ways. To address this need, we developed an integrated rapid access to HIV prevention program for people who inject drugs (iRaPID) that incorporates same-day PrEP and MOUD for this population. Objective: The primary objective of this pilot study is to assess the feasibility and acceptability of the program and evaluate its preliminary efficacy on PrEP and MOUD uptake for a future randomized controlled trial (RCT). We also aim to explore information on the implementation of the program in a real-world setting using a type I hybrid implementation trial design. Methods: Using a type I hybrid implementation trial design, we are pilot testing the nurse practitioner–led iRaPID program while exploring information on its implementation in a real-world setting. Specifically, we will assess the feasibility and acceptability of the iRaPID program and evaluate its preliminary efficacy on PrEP and MOUD uptake in a pilot RCT. The enrolled 50 people who inject drugs will be randomized (1:1) to either iRaPID or treatment as usual (TAU). Behavioral assessments will occur at baseline, and at 1, 3, and 6 months. Additionally, we will conduct a process evaluation of the delivery and implementation of the iRaPID program to collect information for future implementation. Results: Recruitment began in July 2021 and was completed in August 2022. Data collection is planned through February 2023. The Institutional Review Boards at Yale University and the University of Connecticut approved this study (2000028740). Conclusions: This prospective pilot study will test a nurse practitioner–led, integrated HIV prevention program that incorporates same-day PrEP and MOUD for people who inject drugs. This low-threshold protocol delivers integrated prevention via one-stop shopping under the direction of nurse practitioners. iRaPID seeks to overcome barriers to delayed PrEP and MOUD initiation, which is crucial for people who inject drugs who have had minimal access to evidence-based prevention. Trial Registration: ClinicalTrials.gov NCT04531670; https://clinicaltrials.gov/ct2/show/NCT04531670 International Registered Report Identifier (IRRID): DERR1-10.2196/42585


  • Using an Evidence-based Framework to Guide the Implementation of Syringe Services Programs in Jackson, Mississippi

    by William Eger, Kristina Talbert-Slagle, Hannah Allen

    The opioid epidemic in the United States (U.S.) has been coupled with increases in blood-borne infections, including viral hepatitis and human immunodeficiency virus (HIV), which can be spread through injection drug use. The Department of Health and Human Services (HHS) recommends syringe services programs (SSPs) as an evidence-based intervention to address the spread of infectious diseases and to link people who inject drugs (PWID) to appropriate care. Jackson, Mississippi, has one of the highest HIV infection rates in the U.S., yet the city is the only urban area among the top ten incident areas for HIV infections that does not have a sanctioned SSP. The Mississippi State Legislature can request an ‘at-risk’ designation from the Centers for Disease Control and Prevention (CDC), granting them power and funding to establish a SSP to help address increasing blood-borne infections among populations of people who inject drugs. This evidence-based commentary follows the Consolidated Framework for Implementation Research (CFIR) to outline the necessary steps and implementation challenges toward the development of a SSP in Jackson, Mississippi. This framework-based analysis revealed that SSPs have few weaknesses and carry many strengths: SSPs are adaptable, cost-effective, and beneficial for individuals and communities engaged with the programs. SSP development does come with complex political and legal obstacles that have to be untangled, particularly in states like Mississippi, where syringes are classified as drug paraphernalia. In addition to revising laws relating to syringe exchange, implementation of a SSP in Jackson must be accompanied by a grassroots, broad-based marketing and communication campaign led by public health experts who can discuss the benefits of SSPs and combat stigma surrounding injection drug use.